A r t i c l e s Lung cancer remains the leading cause of death from cancer around the world 1 . An estimated 221,000 new cases and 158,000 deaths from lung cancer occurred in the United States alone in 2015 (ref. 2). The two major histological classes are non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLCs mostly comprise lung ADCs and lung SqCCs. These two NSCLC subtypes have both unique and shared clinical and histopathological characteristics. For example, whereas smoking is the major risk factor for both subtypes, approximately 10-15% of lung ADCs are observed in never-smokers 3 . Molecularly targeted therapies directed against receptor tyrosine kinases (RTKs) lead to dramatic responses in subsets of patients with lung ADCs harboring activating genomic alterations in the corresponding kinase genes, including EGFR, ALK, and ROS1 (ref. 4). Other targeted therapies under current investigation are directed against activating alterations in the MET, RET, NTRK1, NTRK2, ERBB2, and BRAF kinases 4,5 .
genes can be challenging because of the large number of passenger mutations that can accumulate from prolonged exposure to tobacco carcinogens and from inherent mutagenic processes such as aberrant activity of APOBEC cytidine deaminases 9 . Profiling larger numbers of samples within a tumor type and combining samples across tumor types can help overcome this problem, by providing the additional statistical power necessary to distinguish important genes mutated at a lower frequency than other genes with passenger mutations 10 . In addition, a comprehensive comparison of recurrently altered genes found in lung ADC and lung SqCC has not been performed. Such analyses may yield insights into the similarities and differences in carcinogenesis between the diseases and elucidate the degree to which common or distinct targeted and immunological therapeutic strategies can be used to treat each cancer type.
RESULTS

Comparison of somatically altered genes
To compare the somatic profiles of lung ADC and lung SqCC and to identify new genetic alterations, we studied 660 lung ADC-normal paired exome sequences (including 274 previously unpublished Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas 6 0 8 VOLUME 48 | NUMBER 6 | JUNE 2016 Nature GeNetics A r t i c l e s cases and 227 previously described cases from The Cancer Genome Atlas (TCGA) 6 together with 159 cases from the cohort in Imielinski et al. 8 ) and 484 lung SqCC-normal paired exome sequences (including 308 previously unpublished cases and 176 previously described cases from TCGA 7 ; Supplementary Tables 1-4) . Similarly to previous studies 6, 7 , we observed median somatic mutation rates of 8.7 mutations/Mb and 9.7 mutations/Mb for lung ADCs and SqCCs, respectively. After excluding genes with lower median expression (log 2 (FPKM) <6. 16 for lung ADCs and <6.27 for lung SqCCs; Online Methods and Supplementary Fig. 1) , we identified 38 genes as significantly mutated in lung ADC and 20 genes as significantly mutated in lung SqCC using MutSig2CV 10 (q value < 0.1; Supplementary Tables 5 and 6). Only six genes-TP53, RB1, ARID1A, CDKN2A, PIK3CA, and NF1-were significantly mutated in both tumor types, and, of these, TP53, CDKN2A, and PIK3CA had a significantly higher mutation frequency in lung SqCC tumors (P < 0.01, Fisher's exact test; Fig. 1a ). Likewise, only 11 of 42 focal amplification peaks were identified as altered in both tumor types ( Fig. 1b) , and 13 of 50 focal deletion peaks were altered in both tumor types ( Fig. 1c) . Interestingly, when compared to 19 other tumor types from TCGA 10 , the lists of significantly mutated genes for lung ADC and lung SqCC had greater overlap with lists of significantly mutated genes from other tumor types (>13% overlap; false discovery rate (FDR) q value < 0.1) than with each other (12% overlap; P = 0.105; Supplementary Fig. 2) , consistent with previous pan-cancer analyses 11 . Recurrently mutated and amplified genes in lung SqCC most closely resembled the genes altered in head and neck squamous cell carcinoma (HNSC) and bladder cancer (BLCA), two other epithelial cancers with epidemiological associations with smoking (>25% overlap; Supplementary Fig. 2) . Among these overlapping genes, TP53, CDKN2A, and FAT1 are specifically enriched for alterations in human papillomavirus (HPV)-negative HNSC 12 . In contrast, the significantly mutated genes in lung ADC were most similar to those in glioblastoma (GBM) and colorectal cancer (CRC) (FDR q value < 0.1). Although lung ADC and lung SqCC did share several focal deletion peaks, five of these peaks are putative fragile sites (shown in green in Fig. 1c ). Taken together, these results suggest that the somatic drivers of carcinogenesis may be largely distinct in lung ADC and lung SqCC.
Mutational signatures in lung cancer
Various carcinogenic and cancer-related processes contribute to the mutational patterns observed in tumors 13, 14 . Previous large-scale studies of lung cancer genomes have identified signatures associated with non-smoking and smoking cases 6, 8, 15 ; here we extend these findings through the improved statistical power of our larger sample set. Using non-negative matrix factorization (NMF) 13, 16 (Online Methods), we identified six mutational signatures in this cohort, many of which are strongly correlated with previously defined signatures in the Catalogue of Somatic Mutations in Cancer (COSMIC) database 13, 17 (Supplementary Figs. 3-5 and Supplementary Table 7 ). These included a UV-related signature of C>T changes at TCC or CCC sites (COSMIC signature 7, abbreviated SI7), a smoking-related signature of C>A transversions (SI4), a mismatch-repair (MMR) signature of C>T changes at GCG sites (SI15/SI6), two APOBECrelated signatures of C>G or C>T changes at TCT or TCA sites (SI13 and SI2), and a final signature with a moderate correlation to COSMIC signature 5 (SI5) with putative 'molecular clock' properties 18 (Supplementary Fig. 5 ). In addition to identifying mutational signatures, NMF also estimates the number of mutations contributed by each signature in each tumor. The estimated number of SI4 (smokingrelated) mutations per megabase displayed a bimodal pattern in lung ADC but not in lung SqCC (Fig. 2a) . Furthermore, the rate of SI4 mutations per megabase was able to classify tumors into those from never-versus ever-smokers substantially better in lung ADC (area under the curve (AUC) = 0.87; Supplementary Fig. 6 ) than in lung SqCC (AUC = 0.62), suggesting that the smoking statuses for the 18 never-smokers with lung SqCC may be inaccurate. Eighty-seven percent of lung ADCs from never-smokers were categorized as transversion low (≤0.696 SI4 mutations/Mb; P = 8.5 × 10 −37 , Fisher's exact test; Fig. 2b and Supplementary Fig. 6 ). However, only 45% of transversion-low lung ADCs were from patients who were never-smokers ( Fig. 2b) . For each tumor, we also derived the fraction of estimated mutations for a signature by dividing the number of estimated mutations for that signature by the sum of estimated mutations from all signatures. Lung SqCCs displayed significantly higher overall rates of SI5 mutations per megabase when compared to all lung ADCs (P < 0.001, Wilcoxon rank-sum test). However, lung ADCs from never-smokers displayed the highest fraction of estimated mutations Figure 1 Distinct somatic alterations in lung ADC and lung SqCC. (a) The MutSig2CV algorithm 10 was used to identify significantly mutated genes across 660 lung ADCs and 484 lung SqCCs. Genes with q values <0.1 were considered to be significantly mutated. The q value for each gene in the lung ADC cohort is plotted against the respective q value in the lung SqCC cohort. The majority of significantly mutated genes were unique to either tumor type. (b,c) The GISTIC 2.0 algorithm was used to identify significantly recurrent copy number gains and losses. The q values for amplifications (b) and deletions (c) in the lung ADC cohort are plotted against the respective q values in the lung SqCC cohort. Peaks with q values <0.25 were considered to be significant. Deletions located within putative fragile sites are highlighted with green labels. Only points corresponding to genes with a previously characterized role in lung cancer are labeled. NS, not significant.
A r t i c l e s from this signature on average ( Fig. 2c and Supplementary Fig. 7) . In lung SqCC, we also observed moderate associations of tumor stage with SI5 activity and total mutation rate (P < 0.01; Supplementary Fig. 8 ).
The mutational profiles of three lung SqCCs (~1% of lung SqCCs) exhibited a pattern of UV-related mutations (SI7) commonly observed in melanoma and displayed a significantly higher mutation rate of somatic single-nucleotide variants (SSNVs) and somatic dinucleotide polymorphisms (DNPs) when compared to the other lung tumors (P < 0.01) but not higher rates of indels (P > 0.05; Fig. 2d ). One of these patients (TCGA-18-3409) had a previous history of basal cell carcinoma in the forehead, raising the possibility that metastasis from the skin to the lung had occurred. The other two lung SqCCs with this signature may also represent squamous cell skin carcinomas metastatic to the lung. The mutational profiles for another seven tumors (four lung ADCs and three lung SqCCs) exhibited an MMR-like signature (SI15/SI6) commonly observed in CRCs with microsatellite instability (MSI) ( Fig. 2e) 13 . These tumors had significantly higher rates of both SSNVs and short indels when compared to all other lung tumors with expression data (P < 0.001). They also displayed lower expression levels of the MMR gene MLH1 (P = 0.011), suggesting a potential etiology for this signature in lung.
New significantly mutated genes
Comparing the significantly mutated genes to those in other tumor types from TCGA Pan-Cancer study 10 showed that there were several genes significantly mutated exclusively in lung ADC, including STK11, RBM10, KEAP1, RAF1, RIT1, and MET (MutSig2CV q value < 0.1; Fig. 3a and Supplementary Table 5 ). NFE2L2, KDM6A, RASA1, NOTCH1, and HRAS were significantly mutated in lung SqCC but not in other cancer types (excluding HNSC and BLCA) ( Fig. 3b and Supplementary Table 6 ). Genes that reached modest statistical significance in lung ADC that have been observed previously to be altered in lung cancer or in other tumor types included AKT1, with a recurrent mutation encoding p.Glu17Lys, CDK4, with a recurrent mutation encoding p.Arg24Leu, and DNMT3A (P < 0.005; Supplementary Table 5 ). The new significantly mutated genes exclusive to lung ADC and which are not altered in other tumor types included PPP3CA, which encodes the catalytic subunit for the calciumdependent phosphatase, calcineurin. The mutations in PPP3CA clustered in the sequence encoding the autoinhibitory domain near the C terminus of the protein, suggesting that they may be gain-of-function alterations (Fig. 4a ). In addition, mutations mapping to the autoinhibitory domain also tended to co-occur with activating KRAS mutations (P = 0.033), suggesting a potential relationship between the K-Ras and calcineurin signaling pathways. Significantly mutated methyltransferase genes included MLL3 (KMT2C) and SETD2. A new gene in this class was the H3K79 methyltransferase DOT1L, which was mutated npg A r t i c l e s in 3% of lung ADCs with enrichment for truncating mutations (Fig. 4a) . Recurrent mutations in lung ADC have previously been reported in splicing factors such as U2AF1, and loss-of-function mutations have been identified in the RNA-binding protein RBM10 (ref. 8 ). In the current data set, a cap methyltransferase, FTSJD1 (also known as CMTR2), was significantly mutated and enriched for frameshift mutations (Fig. 4a) . We also examined genes for other known proteins in this class and found recurrent mutations in SF3B1 (ref. 19 ) and SNRPD3 (Supplementary Fig. 9 ). EGFR mutations were enriched in females, and SMARCA4 mutations were enriched in males (FDR q value < 0.1; Supplementary Table 8 ). RBM10 mutations were modestly enriched in males, as previously reported (q value = 0.219) 6 . The new significantly mutated genes in lung SqCC that were enriched for frameshift mutations (P < 0.001) included RASA1, whose protein product is p120GAP 20 (Fig. 4b) . CUL3, whose protein product is a known interaction partner of KEAP1, also reached statistical significance in the lung SqCC cohort 21 (Fig. 4b) . RB1 mutations were enriched in females, whereas PASK mutations were exclusive to males (FDR q value < 0.1; Supplementary Table 9 ). We did not observe significant associations between mutation status and patient survival or tumor stage after correction for multiple-hypothesis testing ( Supplementary Tables 10-13 ). Controlling for tumor stage did not identify additional significant associations between mutation status and survival. Previous studies have shown that joint analysis of different tumor types can yield additional statistical power to detect low-frequency events, even if the tumor types are from vastly different tissues of origin and/or etiologies 10 . Additionally, although the individual drivers may be distinct between two tumor types, pathways such as mitogenactivated protein (MAP) kinase signaling are often altered similarly in both. We therefore hypothesized that combining the lung ADC and lung SqCC tumor cohorts (into a pan-lung cohort) would identify additional recurrent somatic pathway alterations common to both tumor types. We found 14 genes significantly mutated in the pan-lung cohort that were not significantly mutated in either individual tumor type (q value < 0.1; Supplementary Fig. 10 and Supplementary Table 14) . Many of these genes are involved in epigenetic regulation or immunerelated pathways. KLF5, a transcription factor critical for lung development 22 , contained a new recurrent mutation mapping to the zinc-finger domain, which was observed in both ADCs and SqCCs (Fig. 4c) . A regulator of KLF5, the E3 ubiquitin ligase FBXW7 (ref. 23) , was also significantly mutated in the lung SqCC and pan-lung cohorts but did not co-occur with KLF5 mutations. A super-enhancer duplication associated with increased KLF5 expression has also recently been reported in HNSC by our group 24 , and KLF5 has been reported to be recurrently mutated in BLCA 25 . The paralogs EP300 and CREBBP had a mutational hotspot region mapping to the histone acetyltransferase (HAT) domain. All missense mutations mapping to the HAT domain and other loss-of-function alterations outside this domain were nonoverlapping for these two proteins. For sites with sufficient sequencing depth in the RNA-seq analysis (power >95%), we observed an SSNV validation rate of 88%.
New somatic copy number alterations
With a larger sample size, we had better resolution to detect new copy number changes and ascertain the putative target genes of focal amplifications and deletions. For some peaks that still contained many genes, we inferred the most likely target gene by examining the same peak in a pan-cancer copy number analysis across 11 tumor types 26 that included a subset of the lung cancers from this set. The most significantly focally amplified genes in lung ADC were NKX2-1, MYC, TERT, MCL1, and MDM2 ( Fig. 5a and Supplementary Table 15 ), and peaks at SOX2, CCND1, WHSC1L1-FGFR1, MYC, and EGFR were among the most significant for lung SqCC ( Fig. 5b and Supplementary Table 16 ). Amplification peaks previously described in other tumor types but less characterized in lung tumors included KAT6A, ZNF217, and MYCL1 for lung ADC (Fig. 5a) and IGF1R, KDM5A, PTP4A1-PHF3, and MYCL1 for lung SqCC (Fig. 5b) . CCND3 was specifically amplified in lung ADC, whereas an amplification peak near MIR21-TUBD1 ( Fig. 5c ) was also observed in breast cancer 26 . MIR21 expression has been shown to be a prognostic factor for early-stage ADC 27, 28 . Likewise, new amplification peaks for lung SqCC included YES1, encoding a Src family non-receptor protein kinase, and MIR205 (Fig. 5d) . Expression of MIR205 has been used to distinguish lung SqCCs from other NSCLC types 29 , suggesting that amplification of this microRNA (miRNA) may represent a lineagespecific alteration similar to SOX2 amplification. Finally, combined pan-lung copy number analysis identified additional amplification peaks around MAPK1 (Fig. 5a-d and Supplementary Table 17 ). (a) The q value for each significantly mutated gene in the lung ADC cohort is plotted against the best q value for the same gene in 19 other tumor types from a pan-cancer study 10 .
The q values from the lung SqCC cohort were similarly compared to those from the other tumor types, excluding HNSC and BLCA. The size of each point is proportional to the frequency of mutations in the gene. The color of the point indicates enrichment for mutation clustering as defined by MutSig2CV (-log 10 (P CL )) and/or enrichment for loss-of-function mutations (-log 10 (P value)) as determined with a Fisher's exact test (Online Methods). Black points in the lower-right quadrants represent genes significantly mutated in another cancer type but not in lung ADC and/or lung SqCC.
A r t i c l e s Focal deletion peaks in lung ADC included the chromatin modifier genes SMARCA4 and ARID2 ( Supplementary Fig. 11 and Supplementary Table 18 ), which were also significantly mutated and enriched for loss-of-function mutations. New lung SqCC focal deletions observed in other tumor types included ZMYND11, CREBBP, ROBO1, USP22, and KDM6A ( Supplementary Fig. 11 and Supplementary Table 19 ). B2M (β2 microglobulin), encoding a component of the MHC complex, was focally deleted in both tumor types, was enriched for loss-of-function mutations in both tumor types (P < 0.01), and was significantly mutated in the pan-lung analysis (FDR q value = 0.006). Combined pan-lung copy number analysis identified another focal deletion peak around TRAF3 (Supplementary Table 20) , which was also reported in HNSC 12 . In general, mRNA expression was significantly associated (P < 0.05) with copy number levels for target genes (Supplementary Figs. 12 and 13) . We did not observe substantial batch effects within or across tumor types in either the mRNA expression or copy number variation data ( Supplementary  Figs. 14 and 15) .
Identifying RTK-Ras-Raf drivers in lung ADC
In lung ADC, mutually exclusive alterations have been characterized in components of the RTK-Ras-Raf signaling pathway. These alterations are of particular interest because of the dramatic responses that have been observed to RTK inhibitors in clinical trials such as those for patients with lung ADC harboring EGFR mutation or ALK or ROS1 translocations 30 npg A r t i c l e s activating mutation in the pathway, raising the possibility that additional genes with low-frequency somatic events are yet to be identified. To further understand the somatic landscape of this pathway, we first characterized alterations among known pathway members and then identified new genes with mutually exclusive alterations. New alterations in known pathway genes included a recurrent in-frame insertion in MAP2K1 and a fusion of MET with its neighboring gene, CAPZA2 ( Fig. 6 and Supplementary Table 21 ) 31 . Previously reported TRIM24-NTRK2 and KIF5B-MET fusions 31 were observed in tumors without other known activating alterations. Interestingly, another NTRK2 fusion with TP63 was also found in a lung SqCC ( Fig. 6 and Supplementary Table 21) . As observed previously, high levels of MET and ERBB2 amplification were enriched in tumors without other known activating alterations in this pathway (P < 0.01; Supplementary Fig. 16 ) 6 . A single lung ADC (TCGA-49-4512) harbored an activating EGFR alteration resulting in kinase domain duplication 32 . By manual review, we found additional canonical mutations in KRAS, EGFR, or ERBB2 in 17 tumors and complex indels in EGFR or MET in 11 tumors, some of which have been previously reported 6, 8, 33 ( Supplementary Table 22 ). Lung ADCs that had an activating SSNV, indel, amplification, or gene fusion affecting a known RTK-Ras-Raf driver 6, 34, 35 were designated 'oncogene positive' (n = 418), whereas the remaining lung ADCs were considered 'oncogene negative' (n = 242). For the purposes of this analysis, we did not include NF1-altered tumors in the oncogene-positive group, as mutations in this gene are not entirely mutually exclusive with alterations in other genes related to the RTK-Ras-Raf pathway. To identify additional potential drivers in this pathway, we determined whether genes that were significantly mutated in any of the MutSig2CV analyses (Supplementary Tables 5, 6,  and 14) or that are important in regulation of the Ras pathway 36 were enriched for alterations in oncogene-negative samples using a Fisher's exact test. In total, 15 genes were significantly enriched for alterations among oncogene-negative samples, including the known Ras pathway components SOS1 and RASA1 and the Rho kinase pathway components VAV1 and ARHGAP35 (q value < 0. 1; Fig. 7a,c and Supplementary Table 23 ). SOS1 is a guanine-nucleotide-exchange factor (GEF) bound to the RTK complex and assists in the activation of Ras proteins 37 . Recurrent mutations were observed encoding a p.Asn233Tyr substitution in the autoinhibitory domain (DH) of SOS1 in four lung ADCs, and the p.Asp309Tyr substitution in the same region has been reported in Noonan syndrome 38, 39 (Supplementary  Fig. 17) . Similarly, VAV1 is a GEF for the Rho family GTPases. Interactions between the calponin homology (CH), acidic (Ac), and pleckstrin homology (PH) domains are important for autoinhibition of the catalytic Dbl homology domain 40 . The p.Ser67Tyr substitution is located near the interface of the CH, Ac, and PH domains, and mutagenesis affecting this site has been shown to increase overall GEF activity 40 (Supplementary Fig. 17 ). RASA1 and ARHGAP35 (p190RhoGAP) encode GTPase-activating proteins (GAPs) for the Ras and Rho kinases, respectively, and were each enriched for loss-offunction mutations (P < 0.01). We also identified amplification peaks near FGFR1-WHSC1L1 (8p11.21), PDGFRA-KIT-KDR (4q12), and MAPK1 (22q11) that were only significant in the oncogene-negative tumor set (q value < 0. 25; Fig. 7b,c) . In total, 499 (76%) lung ADCs displayed an alteration in known or putative RTK-Ras-Raf driver genes (Fig. 7c) . Moreover, 193 of 227 (85%) lung ADCs that previously underwent secondary expert pathological review and had RNA-seq data available for fusion analysis 6 harbored a predicted activating alteration in the RTK-Ras-Raf pathway.
New co-occurrences included MET amplifications and NF1 mutations (P = 0.019; Supplementary Fig. 16 ). Additionally, high-level EGFR amplification significantly overlapped with activating EGFR 
ERBB2 MIR205 Figure 5 Significant amplifications in lung cancer. (a) The q value for each amplification peak in lung ADC is plotted against the best q value for the same region across nine other non-lung tumor types 26 . (b) The q values for amplification peaks in lung SqCC are compared against seven other tumor types, excluding HNSC and BLCA. The size of each point is proportional to the frequency of focal amplification. Brackets around gene names indicate that the most likely target gene was inferred from pan-cancer copy number analysis across 11 tumor types or from the combined pan-lung copy number analysis. Black points in the lower-right quadrants indicate genes significantly altered by amplifications in another cancer type but not in lung ADC and/or lung SqCC. (c,d) Gene expression is plotted against focal copy number ratios for new amplification peaks that include CCND3, MIR21, and MAPK1 in lung ADC (c) and YES1, MIR205, and MAPK1 in lung SqCC (d).
npg
A r t i c l e s mutations (P = 1.9 × 10 −8 ) 41, 42 , and STK11 mutations significantly overlapped with activating KRAS mutations (P = 1.1 × 10 −6 ; Fig. 7c) 43, 44 . Furthermore, 28 lung ADCs that remain oncogene negative for the RTK-Ras-Raf pathway harbored STK11 mutations ( Fig. 7c) , suggesting the possibility of an additional, hitherto unrecognized KRAS-related genome alteration complementary to STK11 mutation in these cancer samples.
Assessment of neoantigen load and recurrence
Because of the increasing interest in the use of immune checkpoint inhibitors in lung cancer 45, 46 , we comprehensively analyzed the potential immunogenic properties of the mutational landscape. For each patient, we evaluated the ability of the protein sequence resulting from each somatic missense mutation to be processed and presented to immune cells by any one of the patient-specific HLA alleles 47, 48 . We then assessed the association between the number of immunogenic mutations (resulting in neoepitopes or neoantigens) and clinical characteristics and identified the most common neoepitopes observed in lung cancer. Both nonsynonymous mutation and neoepitope counts were not significantly different between lung ADCs and lung SqCCs from ever-smokers ( Fig. 8a,b) . However, these counts were significantly lower in lung ADCs from never-smokers in comparison to lung ADCs from ever-smokers (P < 0.001, Wilcoxon rank-sum test; Fig. 8a,b ) and were associated with overall smoking history Figure 6 Fusions involving MET and NTRK2. Two fusions of MET were identified that retained the sequence encoding the RTK domain, including one with its neighboring gene, CAPZA2. This fusion most likely arose via tandem duplication resulting in the 3′ end of MET being fused with the 5′ end of CAPZA2. Previously reported TRIM24-NTRK2 and KIF5B-MET fusions 31 were observed in lung ADCs without other known activating alterations in RTK-Ras-Raf signaling. Another NTRK2 fusion with TP63 was also found in a lung SqCC. For each fusion, the expression of exons retained in the putative fusion transcript was relatively higher than the expression of exons not in the putative fusion transcript (as indicated by the gray box). Figure 7 New alterations in the RTK-Rho/ Ras-Raf pathway in lung ADC. Lung ADCs were classified as oncogene positive if they harbored a known activating or recurrent alteration in previously characterized pathway components and were classified as oncogene negative otherwise. (a) Fifteen genes (red points) were significantly enriched for mutations among oncogene-negative tumors (Fisher's exact test, FDR q value < 0.1; supplementary table 23). A log-transformed odds ratio (LOR) greater than 0 indicates that the frequency of mutations was higher in the oncogene-negative set. (b) Significant amplification peaks near FGFR1-WHSC1L1, PDGFRA-KIT-KDR, and MAPK1 were only found in the oncogene-negative tumor set using GISTIC 2.0 (q value < 0.25). (c) Comutation plot for known and new activators of the pathway. Tumors were considered to have high-level amplification for a given gene if they had a total log 2 -transformed copy number ratio greater than 1. For genes with gain-of-function SSNVs or indels, only recurrently mutated sites or sites with previous experimental functional evidence were included. New genes enriched for alterations among oncogene-negative tumors that are members of the RTK-Rho/Ras-Raf pathway are labeled in red in all panels. Dashed lines separate tumors that harbor a known or putative alteration in this pathway (n = 499), tumors that do not harbor an alteration in this pathway but have a mutation in STK11 (n = 28), and tumors that do not harbor an alteration in this pathway or STK11 (n = 133). NA, RNA-seq data were not available.
A r t i c l e s in lung ADCs but not lung SqCCs (P < 0.001, Kruskal-Wallis test; Supplementary Fig. 18) . Alterations predicted to generate neoepitopes in at least four tumors included PIK3CA p.Glu542Lys, NFE2L2 p.Glu79Gln, B-Raf p.Gly466Val, EGFR p.Gly719Ala, and several alterations in TP53, including p.Val157Phe, p.Gly154Val, p.Arg175Gly, and p.Pro278Ala (Fig. 8c) . A gene not previously implicated in lung cancer, C3orf59 (also known as MB21D2), harbored a recurrent mutation encoding p.Gln311Glu, which has predicted neoepitope properties (Fig. 8c) . Overall, 47% of lung ADC and 53% of lung SqCC samples had at least five predicted neoepitopes, suggesting great potential for immunotherapy.
DISCUSSION
We examined the exome sequences and copy number profiles of 1,144 lung cancers to explore similarities and differences between lung ADC and lung SqCC. Consistent with studies of gene expression 11 , this comparison showed that both mutated genes and recurrent somatic copy number alterations are largely distinct for the two lung cancer types. The similarity between lung SqCCs, HNSCs, and a subset of BLCAs was also observed when 12 tumor types were reclassified using clustering of five molecular data types 11 . These differences suggest that somatic alterations can have different oncogenic potential in different cellular contexts. Thus, cancers arising from developmentally similar cells of origin across different tissues will be more similar than cancers arising from different cells of origin within an anatomically defined tissue. As we had only one tumor sample per patient, we were not able to analyze intratumoral heterogeneity, as has been done in other studies 49, 50 .
Several new focal amplification peaks containing proteincoding genes, including MAPK1, YES1, and CCND3, were identified. Interestingly, we also found two peaks that contained or were near miRNA genes (MIR21 in lung ADC and MIR205 in lung SqCC). We have also recently reported the duplication of a noncoding super-enhancer that results in increased MYC expression 24 . As the mutational analyses in this study focused on whole-exome sequencing of protein-coding genes, we were not able to examine mutations in noncoding genes or regulatory elements. Future studies examining large numbers of whole genomes from lung cancer may be better suited for discovery of other oncogenic alterations in noncoding genes or regulatory elements.
Our study has uncovered multiple significantly mutated genes in the RTK-Ras-Raf pathway, including newly identified genes such as RASA1, SOS1, and VAV1. Previous studies examining smaller numbers of lung tumors were not able to detect recurrent mutations in SOS1 (refs. 8,39) . The fact that we were able to detect these mutants further highlights the usefulness of increasing sample size to detect rare events. Because we did not have matching RNA-seq data for every tumor, we may be underestimating the rates of oncogenic fusions or MET exon 14 skipping events. As 15-25% of lung ADCs still do not have a known, detectable alteration in the RTK-Ras-Raf pathway, we may yet be underpowered to find additional rare, recurrent mutations in known and new pathway components. Similar considerations may be relevant for other pathways. For example, we identified new epigenetic modifier mutations in CREBBP and EP300, previously shown in SCLC 51 .
Finally, we examined the immunogenicity of individual missense mutations to understand more fully the association between neoepitope loads, overall nonsynonymous mutation rates, and clinical variables such as smoking status. Some highly recurrent mutations were predicted to result in neoepitopes. Future studies may further unravel the relationship between these candidates and clinical responses to immune checkpoint inhibitors and customized vaccine therapies.
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